Navigation Links
Enhanced cord blood stem cell transplants safe in long-term studies
Date:4/18/2011

BOSTON--An innovative experimental treatment for boosting the effectiveness of stem-cell transplants with umbilical cord blood has a favorable safety profile in long-term animal studies, report scientists from Dana-Farber Cancer Institute, Beth Israel Deaconess Medical Center (BIDMC), and Children's Hospital Boston (CHB).

Analysis of long-term safety testing in nonhuman primates, published online by the journal Cell Stem Cell, revealed that, after one year following transplant, umbilical cord blood units treated with a signaling molecule called 16,16-dimethyl PGE2 reconstituted all the normal types of blood cells, and none of the animals receiving treated cord blood units developed cancer. Wolfram Goessling, MD, PhD, of Dana-Farber and Brigham and Women's Hospital, is the first author of the paper, and Trista North, PhD, of BIDMC is the senior author.

The results of long-term safety studies in mice were previously submitted to the Food and Drug Administration to gain permission for a Phase 1 clinical trial under an Investigational New Drug (IND) application. Principal investigator, Corey Cutler, MD, a Dana-Farber transplant specialist, initiated the trial in 2009 at Dana-Farber and the Massachusetts General Hospital. The IND is sponsored by Fate Therapeutics, Inc. of San Diego.

Goessling and North were post-doctoral fellows in the laboratory of co-author Leonard Zon, MD, a stem cell researcher at CHB and a scientific founder of Fate Therapeutics, when they hit upon 16,16-dimethyl PGE2 while looking for compounds that could regulate the production of hematopoietic stem cells. The initial testing made use of zebra fish models. Goessling commented that "this is the first time a compound discovered in zebra fish has received a nod from the FDA for a clinical trial."

One of the limitations of cord blood as a transplant source is the cells engraft, or "take," in the recipient's bone marrow more slowly than matched donor cells form bone marrow. In addition, there is a higher failure rate for cord blood transplants. Thus there is a need for ways to improve the speed and quality of cord blood transplantation.


'/>"/>

Contact: Bill Schaller
william_schaller@dfci.harvard.edu
617-632-5357
Dana-Farber Cancer Institute
Source:Eurekalert  

Related medicine news :

1. Efficacy of tuberculosis vaccine enhanced
2. Enhanced early childhood education pays long-term dividends in better health
3. More lives saved with 24/7 enhanced staffing in medical ICU
4. My1Stop.com Improves Customer Experience with Enhanced Online Printing Web Site Design
5. Horizon Display Demonstrates their Dedication to After-Sales Support with Enhanced Online Resources
6. Orion Health Helps Northumbria Healthcare NHS Foundation Trust Deliver an Enhanced Electronic Patient Record
7. Provalis Research Announces the Release of WordStat 6, Delivering Enhanced Analytical and Visualization Tools for Textual Data
8. 1Dental.com Announces Enhanced Broker-Affiliate Program
9. SumNuts Vitamin Nuts Launched, Enhanced with Vitamin D3 and Calcium
10. DST Health Solutions Releases Enhanced ACG System to Help Health Plans Improve Member Health
11. Acuo Technologies Announces Enhanced Offerings That Facilitate Management of Non-DICOM Objects
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Enhanced cord blood stem cell transplants safe in long-term studies
(Date:1/16/2017)... (PRWEB) , ... January 16, 2017 , ... ... in the Aesthetic Surgery Journal , the official journal of The American ... on lower eyelid retraction surgery. The procedure is designed to correct drooping, retracted ...
(Date:1/16/2017)... ... January 16, 2017 , ... ... Chief Executive Officer of the medical device company, effective immediately. , “This is ... “Kevin has a strong track record in medical device market development and ...
(Date:1/15/2017)... ... 2017 , ... Whole Health Supply, LLC is announcing the release of an updated version of ... purchase. , The 2017 edition has wide jaws that will accommodate nails up to ... well as diabetics. This handle is reinforced for extra strength when pressing down on dense ...
(Date:1/15/2017)... ... , ... Wondering where to go this Valentine's Day? Well, there is a ... romantic, lobster feast in the comfort of your own home. Lobster Gram is introducing ... be featured until February 15th, 2017. , Romantic Dinner one is Lobster Gram's ...
(Date:1/14/2017)... ... 2017 , ... According to a December 9 article ... the risk of type 2 diabetes, Alzheimer’s, and cardiovascular disease. Southern California based ... linked to a Mediterranean diet are only some of the many reasons that ...
Breaking Medicine News(10 mins):
(Date:1/16/2017)... 2017  Rigel Pharmaceuticals (Nasdaq: RIGL ) ... 16, 2017 the Compensation Committee of Rigel,s Board of ... purchase an aggregate of 214,000 shares of common stock ... to the Rigel Pharmaceuticals, Inc. Inducement Plan, as amended, ... into employment with Rigel, in accordance with NASDAQ Listing ...
(Date:1/16/2017)... -- CBDRx, the world,s premiere nutraceutical hemp company, is ... extract to Veteran,s groups across the country. ... to Veteran,s groups across the United States.  Passion is ... world and through their passion, CBDRx honors our Veterans ... hemp extract available. ...
(Date:1/15/2017)... -- Le conseil d,administration de SurgaColl Technologies Ltd., ... la régénération de tissus humains, annonce la nomination de ... effet immédiat. ... Bill est un dirigeant expérimenté à l,international dans l,industrie ... générale et de direction au sein de sociétés internationales spécialisées ...
Breaking Medicine Technology: